Yee Liong Lee, MD
Endocrinology, Diabetes & Metabolism · Carson City, NVNPI 1699296392
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NV, where the typical reported total is $4,060.
Across 172 payments — averaging $26.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$541
- Boehringer Ingelheim$490
- Lilly USA, LLC$487
- Medtronic$357
- AstraZeneca$287
- Insulet Corporation$243
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,636100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 15 | $541 |
| Boehringer Ingelheim | 15 | $490 |
| Lilly USA, LLC | 25 | $487 |
| Medtronic | 19 | $357 |
| AstraZeneca | 8 | $287 |
| Insulet Corporation | 13 | $243 |
| Novo Nordisk | 6 | $234 |
| Abbott | 10 | $200 |
| Mannkind Corporation | 8 | $175 |
| Dexcom, Inc. | 3 | $166 |
| Chiesi USA, Inc. | 1 | $148 |
| Sanofi-aventis U.S. LLC | 2 | $147 |
| Xeris Pharmaceuticals, Inc. | 7 | $144 |
| Ascendis Pharma Endocrinology Inc | 3 | $134 |
| Kyowa Kirin, Inc. | 5 | $131 |
| AbbVie | 5 | $117 |
| Corcept Therapeutics | 3 | $117 |
| Recordati_rare_diseases_inc. | 5 | $107 |
| Tandem Diabetes Care, Inc. | 6 | $96 |
| Ascensia Diabetes Care US Inc. | 2 | $94 |
| Almatica Pharma LLC | 2 | $46 |
| Bayer | 2 | $42 |
| IBSA Pharma Inc. | 2 | $29 |
| Radius Health, Inc. | 1 | $24 |
| RGH Enterprises LLC | 1 | $22 |
| Halozyme Inc | 1 | $22 |
| Rhythm Pharmaceuticals, Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,636 in reported general payments places this provider in the 50th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 270 | $449,660 |
| MounjaroTirzepatide | 141 | $196,685 |
| JardianceEmpagliflozin | 146 | $183,091 |
| TrulicityDulaglutide | 56 | $109,012 |
| TymlosAbaloparatide | 25 | $72,446 |
| Gvoke Hypopen 2-PackGlucagon | 75 | $46,565 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $41,081 |
| Novolog FlexpenInsulin Aspart | 110 | $37,526 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 30 | $34,919 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $31,927 |
| RybelsusSemaglutide | 16 | $27,554 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $27,079 |
| FarxigaDapagliflozin Propanediol | 12 | $20,439 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 139 | $20,275 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $18,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $234 | $483,135301 claims |
| Lilly USA, LLCMounjaro, Trulicity | $487 | $305,698197 claims |
| Boehringer IngelheimJardiance | $490 | $183,091146 claims |
| Radius Health, Inc.Tymlos | $24 | $72,44625 claims |
| AstraZenecaFarxiga | $287 | $20,43912 claims |
| AbbVieSynthroid | $117 | $6,91866 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Carson City
- Eng Keong TanCarson City$12K
- Joi HesterCarson City$9K
- John SuttonCarson City$8K
- Nitesh KuhadiyaReno$595K
- Samer NakhleLas Vegas$466K
- Quang NguyenHenderson$378K
- William LitchfieldHenderson$288K
- Chakravarthy KannanLas Vegas$144K
- Lisa AbbottReno$130K
- Michael Raymund GonzalesReno$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.